BBNX — Beta Bionics Cashflow Statement
0.000.00%
- $870.27m
- $620.55m
- $65.12m
- 45
- 23
- 96
- 55
Annual cashflow statement for Beta Bionics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Net Income/Starting Line | -64.8 | -44.1 | -54.8 |
| Depreciation | |||
| Non-Cash Items | 5.99 | 15.7 | 17.5 |
| Unusual Items | |||
| Other Non-Cash Items | |||
| Changes in Working Capital | -2.79 | -5.3 | -12.1 |
| Change in Accounts Receivable | |||
| Change in Inventories | |||
| Change in Prepaid Expenses | |||
| Change in Other Assets | |||
| Change in Accounts Payable | |||
| Change in Accrued Expenses | |||
| Change in Other Liabilities | |||
| Cash from Operating Activities | -60.2 | -32.4 | -48.3 |
| Capital Expenditures | -0.772 | -0.402 | -3.4 |
| Purchase of Fixed Assets | |||
| Other Investing Cash Flow Items | 0.003 | -69.3 | -0.081 |
| Sale of Fixed Assets | |||
| Sale/Maturity of Investment | |||
| Purchase of Investments | |||
| Cash from Investing Activities | -0.769 | -69.7 | -3.48 |
| Financing Cash Flow Items | — | — | -4.15 |
| Other Financing Cash Flow | |||
| Net Issuance / Retirement of Stock | |||
| Cash from Financing Activities | 56.8 | 101 | 55.6 |
| Beginning Cash Balance | |||
| Ending Cash Balance | |||
| Net Change in Cash | -4.2 | -1.11 | 3.87 |